Result of EGM

RNS Number : 2826P

Ovoca Bio PLC

16 February 2021

 

Ovoca Bio plc

("Ovoca" or the "Company")

Result of Extraordinary General Meeting

Dublin, Ireland, 16 February 2021 - Ovoca Bio plc (LSE: OVB; ISE: OVXA), a biopharmaceutical company with a focus on women's health, announces that each of the resolutions proposed at the Extraordinary General Meeting of the Company, held earlier today, were passed. 

The full text of each resolution was included in the Notice of Extraordinary General Meeting of the Company, circulated to shareholders on 25 January 2021. The resolutions relate to the replacement of CREST with Euroclear Bank for electronic settlement of trading in the ordinary shares of the Company.

Voting on the resolutions was conducted by poll, and the details of the poll vote are set out below:

	Votes for	%	Votes Against	%	Votes Total	% of ISC Voted	Votes Withheld
Resolution 1: Shareholders Consent to Migration	35,370,233	99.99	1,880	0.01	35,372,113	39.99	0
Resolution 2: Approval and Adoption of New Articles of Association of the Company	35,370,233	99.99	1,880	0.01	35,372,113	39.99	0
Resolution 3: to give effect to aspects of the Migration	35,370,233	99.99	1,880	0.01	35,372,113	39.99	0

Notes

1.  Any proxy appointments which gave discretion to the Chair have been included in the "votes for" total.

2.  A "Vote Withheld" is not a valid vote in Irish law and was not counted in the calculation of the proportion of the votes "For" or "Against" a resolution.

 

End

For further information:

Ovoca Bio plc

Kirill Golovanov (Chief Executive)

Tel [phone]

[e-mail]

Davy (Nominated Adviser, Euronext Growth Advisor and Broker)

John Frain / Daragh O'Reilly

Tel: [phone]

Consilium Strategic Communications

Chris Gardner, Chris Welsh, Carina Jurs

[e-mail]

Tel: [phone]

About Ovoca Bio

Ovoca Bio is a European-based biopharmaceutical company with a focus on women's health. The Company is currently developing a novel treatment for women with hypoactive sexual desire disorder (HSDD). 

The Company's lead product, BP-101, a novel synthetic peptide administered through a nasal spray, is clinically validated, with Phase II and Phase III studies conducted in Russia demonstrating statistically significant improvement in a number of key efficacy outcomes, including an increase in female sexual desire and reduction of symptoms of distress associated with HSDD.

Ovoca Bio is seeking to develop the drug for major global markets - in particular the United States and Europe, as well as obtain marketing approval in the Russian Federation.

 

 

END

 

 

ROMDZGMZFVDGMZM